A self-assembled polymeric micellar immunomodulator for cancer treatment based on cationic amphiphilic polymers

Biomaterials

Volumn 35, Issue 37, 2014, Pages 9912-9919

  Yim, Hyeona ^a   Park, Wooram ^a   Kim, Dongin ^b   Fahmy, Tarek M ^b,c   Na, Kun ^a  

^a The Catholic University of Korea   (South Korea)

^b Yale University   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Antitumor immune responses; Cancer; Cationic polymer; Necrosis; Self assembly

Indexed keywords

CELL DEATH; CELL PROLIFERATION; CONJUGATED POLYMERS; DRUG PRODUCTS; HYALURONIC ACID; IMMUNE SYSTEM; MAMMALS; MICELLES; SELF ASSEMBLY; TUMORS;

ALL-TRANS RETINOIC ACIDS; ANTI-TUMOR IMMUNE; ANTICANCER ACTIVITIES; CANCER; CATIONIC POLYMERS; LOW MOLECULAR WEIGHT; NECROSIS; SYSTEMIC ADMINISTRATION;

DISEASES;

AMPHOPHILE; CISPLATIN; DOXORUBICIN; HYALURONIC ACID; IMMUNOMODULATING AGENT; POLYMER; RETINOIC ACID; SELF ASSEMBLED POLYMERIC MICELLAR IMMUNOMODULATOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CATION; CYTOKINE; IMMUNOLOGIC FACTOR; MICELLE; POLYETHYLENEIMINE; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL MEMBRANE; CONTROLLED STUDY; DNA DEGRADATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MALE; MOLECULAR WEIGHT; MOUSE; MTT ASSAY; NEOPLASM; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; SURFACE CHARGE; SYSTEMIC THERAPY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; IMMUNOLOGY; MICELLE; NEOPLASMS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATIONS; CELL LINE, TUMOR; CYTOKINES; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NEOPLASMS; POLYETHYLENEIMINE; SURFACE-ACTIVE AGENTS; TRETINOIN;

EID: 84907266448     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.029     Document Type: Article

References (40)

1. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007, 59:491-504.
2. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl J Med 2004, 350:2129-2139.
4. Parsons D.W., Jones S., Zhang X., Lin J.C.-H., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
5. Park J., Wrzesinski S.H., Stern E., Look M., Criscione J., Ragheb R., et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater 2012, 11:895-905.
6. Mejías R., Pérez-Yagüe S., Gutiérrez L., Cabrera L.I., Spada R., Acedo P., et al. Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided invivo delivery of interferon gamma for cancer immunotherapy. Biomaterials 2011, 32:2938-2952.
7. Son Y.J., Kim H., Leong K.W., Yoo H.S. Multifunctional nanorods serving as nanobridges to modulate T cell-mediated immunity. ACS Nano 2013, 7:9771-9779.
8. Phua K.K., Staats H.F., Leong K.W., Nair S.K. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep 2014, 4:5128.
9. Peng B.G., Liu S.Q., Kuang M., He Q., Totsuka S., Huang L., et al. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res 2002, 93:363-368.
10. Hanes J., Sills A., Zhao Z., Suh K.W., Tyler B., DiMeco F., et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 2001, 18:899-906.
11. Christian D.A., Hunter C.A. Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy 2012, 4:425-441.
12. Huang Z., Yang Y., Jiang Y., Shao J., Sun X., Chen J., et al. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials 2013, 34:746-755.
13. Yim H., Park S.-J., Bae Y.H., Na K. Biodegradable cationic nanoparticles loaded with an anticancer drug for deep penetration of heterogeneous tumours. Biomaterials 2013, 34:7674-7682.
14. Yim H., Na K. Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells. Biomacromolecules 2010, 11:2387-2393.
15. Wang Y., Zheng M., Meng F., Zhang J., Peng R., Zhong Z. Branched polyethylenimine derivatives with reductively cleavable periphery for safe and efficient invitro gene transfer. Biomacromolecules 2011, 12:1032-1040.
16. He Y., Cheng G., Xie L., Nie Y., He B., Gu Z. Polyethyleneimine/DNA polyplexes with reduction-sensitive hyaluronic acid derivatives shielding for targeted gene delivery. Biomaterials 2013, 34:1235-1245.
17. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. Invitro cytotoxicity testing of polycations: influence of structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
18. Necas J., Bartosikova L., Brauner P., Kolar J. Hyaluronic acid (hyaluronan): a review. Vet Med 2008, 53:397-411.
19. Stern R. In hyaluronidases in cancer biology 2008, 275-280. seminars in cancer biology, Elsevier.
20. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
21. Girish K., Kemparaju K., Nagaraju S., Vishwanath B.S. Hyaluronidase inhibitors: a biological and therapeutic perspective. Curr Med Chem 2009, 16:2261-2288.
22. Park K.M., Kang H.C., Cho J.K., Chung I.-J., Cho S.-H., Bae Y.H., et al. All-trans-retinoic acid (ATRA)-grafted polymeric gene carriers for nuclear translocation and cell growth control. Biomaterials 2009, 30:2642-2652.
23. Park W., Kim D., Kang H.C., Bae Y.H., Na K. Multi-arm histidine copolymer for controlled release of insulin from poly(lactide-co-glycolide) microsphere. Biomaterials 2012, 33:8848-8857.
24. Leroueil P.R., Berry S.A., Duthie K., Han G., Rotello V.M., McNerny D.Q., et al. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett 2008, 8:420-424.
25. Bajaj A., Kondaiah P., Bhattacharya S. Synthesis and gene transfection efficacies of PEI-cholesterol-based lipopolymers. Bioconjug Chem 2008, 19:1640-1651.
26. Boulikas T., Vougiouka M. Cisplatin and platinum drugs at the molecular level (review). Oncol Rep 2003, 10:1663-1682.
27. McLellan L.I., Wolf C.R. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updat 1999, 2:153-164.
28. 2 bubbles to induce transient cavitation, lysosomal rupturing, and cell necrosis. Angew Chem Int Ed 2012, 124:10089-10093.
29. Fischer D., Bieber T., Li Y., Elsässer H.-P., Kissel T. Anovel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999, 16:1273-1279.
30. Crider B.P., Xie X.-S., Stone D.K. Bafilomycin inhibits proton flow through the H+ channel of vacuolar proton pumps. JBiol Chem 1994, 269:17379-17381.
31. Tsafrir I., Sagi D., Arzi T., Guedeau-Boudeville M.-A., Frette V., Kandel D., et al. Pearling instabilities of membrane tubes with anchored polymers. Phys Rev Lett 2001, 86:1138-1141.
32. Yang X.Z., Du X.J., Liu Y., Zhu Y.H., Liu Y.Z., Li Y.P., et al. Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy. Adv Mater 2013, 26:931-936.
33. Wang S., Mi J.-B., Li Y.-Z., Chang W.-B., Ci Y.-X., Zhao M.-Z., et al. Pharmacokinetics and tissue distribution of IV injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats. Acta Pharmacol Sin 2003, 24:589-592.
34. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy invivo. Proc Natl Acad Sci U S A 2011, 108:1850-1855.
35. Chen G.Y., Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010, 10:826-837.
36. Sheth S.G., Flamm S.L., Gordon F.D., Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998, 93:44-48.
37. Giannini E., Botta F., Fasoli A., Ceppa P., Risso D., Lantieri P.B., et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999, 44:1249-1253.
38. Wang S., Huang P., Nie L., Xing R., Liu D., Wang Z., et al. Single continuous wave laser induced photodynamic/plasmonic photothermal therapy using photosensitizer-functionalized gold nanostars. Adv Mater 2013, 25:3055-3061.
39. Tang H.L., Yuen K.L., Tang H.M., Fung M.C. Reversibility of apoptosis in cancer cells. Br J Cancer 2009, 100:118-122.
40. Kim D.-H., Rozhkova E.A., Ulasov I.V., Bader S.D., Rajh T., Lesniak M.S., et al. Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat Mater 2010, 9:165-171.